TBX-3400

BIOLOGICAL2 trials

Sponsors

Taiga Biotechnologies, Inc.

Conditions

CancerRefractory CancerStage III MelanomaStage IV MelanomaTumor, Solid

Phase 1

Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors

Taiga Biotechnologies, Inc.Stage III Melanoma, Stage IV Melanoma

Start: 2019-06-02End: 2024-12-31Target: 72Updated: 2022-05-03

Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

Taiga Biotechnologies, Inc.Cancer, Refractory Cancer, Tumor, Solid

Start: 2021-01-25End: 2023-04-30Target: 60Updated: 2022-02-02